Hancock Jaffe Laboratories, Inc. announced that it appointed, upon the recommendation of the Nominating Committee of the Board, Matthew Jenusaitis and Robert Gray to fill two vacancies on the Board. Mr. Jenusaitis has been appointed to fill the vacancy on the Board left by Marc Robins, who passed away in April, and Mr. Gray has been appointed to fill the vacancy on the Board left by Yury Zhivilo, who resigned from the Company at the end of May 2019. Each of the new directors qualifies as “independent” under Nasdaq Stock Market rules. Mr. Jenusaitis, who has been appointed as a Class II director and will serve as a member of Audit, Compensation and Nominating and Corporate Governance Committees, has over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases. Mr. Gray, who has been appointed as a Class III director, has also been appointed to the Audit Committee of the Board as its Chairman and will also serve as a member of Compensation Committee, had a 20-year career at Highmark, Inc., one of America’s largest health insurance organizations, which serves over 20 million subscribers, and includes Highmark Blue Cross Blue Shield Pennsylvania, Highmark Blue Cross Blue Shield Delaware, and Highmark Blue Cross Blue Shield West Virginia, which he retired from in 2008.